Acadia Pharmaceuticals (ACAD) PT Lowered to $35 at UBS, Stock Still a 'Top Idea'
Tweet Send to a Friend
UBS analyst Ashwani Verma lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $35.00 (from $39.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
